Novartis dealt another setback to broader Menveo use

Novartis ($NVS) hit another snag in its quest to broaden use of the meningococcal vaccine Menveo. The FDA has asked for more information on Menveo use in infants, delaying the company's ability to market the shot for that group. The setback could hobble Menveo as it seeks to compete with Sanofi's ($SNY) Menactra, an analyst told Dow Jones. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.